Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease

Identifieur interne : 008909 ( Main/Merge ); précédent : 008908; suivant : 008910

Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease

Auteurs : L. V. Metman [États-Unis] ; P. J. Blanchet [États-Unis] ; D. De Jong [États-Unis] ; M. M. Mouradian [États-Unis] ; T. N. Chase [États-Unis]

Source :

RBID : Pascal:96-0244005

Descripteurs français

English descriptors


Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:96-0244005

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Effect of the putative dopamine D
<sub>1</sub>
agonist and D
<sub>2</sub>
antagonist FCE 23884 on Parkinson's disease</title>
<author>
<name sortKey="Metman, L V" sort="Metman, L V" uniqKey="Metman L" first="L. V." last="Metman">L. V. Metman</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="De Jong, D" sort="De Jong, D" uniqKey="De Jong D" first="D." last="De Jong">D. De Jong</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T. N." last="Chase">T. N. Chase</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">96-0244005</idno>
<date when="1996">1996</date>
<idno type="stanalyst">PASCAL 96-0244005 INIST</idno>
<idno type="RBID">Pascal:96-0244005</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003394</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003430</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003377</idno>
<idno type="wicri:doubleKey">0885-3185:1996:Metman L:effect:of:the</idno>
<idno type="wicri:Area/Main/Merge">008909</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Effect of the putative dopamine D
<sub>1</sub>
agonist and D
<sub>2</sub>
antagonist FCE 23884 on Parkinson's disease</title>
<author>
<name sortKey="Metman, L V" sort="Metman, L V" uniqKey="Metman L" first="L. V." last="Metman">L. V. Metman</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="De Jong, D" sort="De Jong, D" uniqKey="De Jong D" first="D." last="De Jong">D. De Jong</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T. N." last="Chase">T. N. Chase</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="1996">1996</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Agonist</term>
<term>Antagonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>D1 Dopamine receptor</term>
<term>D2 Dopamine receptor</term>
<term>Ergoline derivatives</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Parkinson maladie</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D1</term>
<term>Antagoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Ergoline dérivé</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Antiparkinsonien</term>
<term>FCE 23884</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Maryland</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="Maryland">
<name sortKey="Metman, L V" sort="Metman, L V" uniqKey="Metman L" first="L. V." last="Metman">L. V. Metman</name>
</region>
<name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name>
<name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T. N." last="Chase">T. N. Chase</name>
<name sortKey="De Jong, D" sort="De Jong, D" uniqKey="De Jong D" first="D." last="De Jong">D. De Jong</name>
<name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008909 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 008909 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:96-0244005
   |texte=   Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024